Breaking News

Sterling Pharma Completes Acquisition of Novartis API Mfg. Facility

Provides additional capacity for Sterling’s API manufacturing services, and the deal includes an on-going supply agreement.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sterling Pharma Solutions, a global contract development and manufacturing organization, has completed its acquisition of an active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, from Novartis. The facility will provide additional capacity for Sterling’s growing API manufacturing services, and the deal includes an on-going supply agreement with Novartis to continue to manufacture several APIs for cardiovascular, immunology and oncology medicines at Ringaskiddy. F...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters